Correlation between Heart fatty acid binding protein and severe COVID-19: A case-control study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
02
2020
accepted:
26
03
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
6
5
2020
Statut:
epublish
Résumé
Heart-fatty acid binding protein (HFABP) has been recognized as a highly heart-specific marker. However, it is currently unknown that its HFABP is also closely related to the severity of COVID-19. We retrospectively screened 46 patients who met our inclusion criteria within 4 weeks. They were tested for HFABP after the diagnosis of COVID-19, and monitored for HFABP during their hospital stay. We tracked the patients during their hospital stay to determine if they had severe COVID-19 or mild-to-severe transition features. We calculated the chi-square test values found for HFABP to predict the correlation between HFABP levels and the severity of the COVID-19. Of these 46 cases, 16 cases with confirmed COVID-19 were tested for HFABP> 7 ng / mL upon admission; among them, 14 cases were diagnosed with severe COVID-19 within the hospitalization. The Odds ratio of the measured HFABP elevation was 6.81(95% confidence interval [CI] 5.23-8.40), and 3 patients with severe COVID-19 progressed in 5 patients with mild HFABP> 7 ng/mL. These data indicate that the elevation of HFABP is closely related to the severity of COVID-19 in the patients, and the elevated HFABP may cause rapid development of patients with mild COVID-19 into severe COVID-19. But serum HFABP negative maybe make patients with mild COVID-19 safer, the current data show no effect on the all-cause mortality. Our study has been registered with the Chinese Clinical Trial Registry, the registration number: ChiCTR2000029829.
Sections du résumé
BACKGROUND
Heart-fatty acid binding protein (HFABP) has been recognized as a highly heart-specific marker. However, it is currently unknown that its HFABP is also closely related to the severity of COVID-19.
METHODS
We retrospectively screened 46 patients who met our inclusion criteria within 4 weeks. They were tested for HFABP after the diagnosis of COVID-19, and monitored for HFABP during their hospital stay. We tracked the patients during their hospital stay to determine if they had severe COVID-19 or mild-to-severe transition features. We calculated the chi-square test values found for HFABP to predict the correlation between HFABP levels and the severity of the COVID-19.
RESULTS
Of these 46 cases, 16 cases with confirmed COVID-19 were tested for HFABP> 7 ng / mL upon admission; among them, 14 cases were diagnosed with severe COVID-19 within the hospitalization. The Odds ratio of the measured HFABP elevation was 6.81(95% confidence interval [CI] 5.23-8.40), and 3 patients with severe COVID-19 progressed in 5 patients with mild HFABP> 7 ng/mL.
CONCLUSION
These data indicate that the elevation of HFABP is closely related to the severity of COVID-19 in the patients, and the elevated HFABP may cause rapid development of patients with mild COVID-19 into severe COVID-19. But serum HFABP negative maybe make patients with mild COVID-19 safer, the current data show no effect on the all-cause mortality.
TRIAL REGISTRATION
Our study has been registered with the Chinese Clinical Trial Registry, the registration number: ChiCTR2000029829.
Identifiants
pubmed: 32348339
doi: 10.1371/journal.pone.0231687
pii: PONE-D-20-05567
pmc: PMC7190125
doi:
Substances chimiques
FABP3 protein, human
0
Fatty Acid Binding Protein 3
0
Banques de données
ChiCTR
['ChiCTR2000029829']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0231687Déclaration de conflit d'intérêts
No authors have competing interests.
Références
Lancet. 2003 Jul 26;362(9380):263-70
pubmed: 12892955
Br Heart J. 1994 Feb;71(2):135-40
pubmed: 8130020
Cytokine. 2018 Apr;104:8-13
pubmed: 29414327
Nature. 2013 Nov 28;503(7477):535-8
pubmed: 24172901
N Engl J Med. 2003 May 15;348(20):1967-76
pubmed: 12690091
Lancet Infect Dis. 2013 Sep;13(9):752-61
pubmed: 23891402
Mol Cell Biochem. 1992 Oct 21;116(1-2):155-62
pubmed: 1480144
Virol Sin. 2013 Dec;28(6):315-7
pubmed: 24174406
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
J Pathol. 2006 Nov;210(3):288-97
pubmed: 17031779
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
J Virol. 2013 Jul;87(14):7790-2
pubmed: 23678167
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Nat Med. 2013 Oct;19(10):1313-7
pubmed: 24013700
J Coll Physicians Surg Pak. 2018 Jan;28(1):56-60
pubmed: 29290194
PLoS One. 2014 Feb 14;9(2):e88716
pubmed: 24551142